NCT01451619View on ClinicalTrials.gov

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Rosacea
Interventions
DRUG

Laropiprant

One 100-mg tablet orally once daily for 4 weeks

DRUG

Placebo for Laropiprant

One tablet orally once daily for 4 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01451619 - A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155) | Biotech Hunter | Biotech Hunter